03.October.2011Takeda Pharmaceuticals today announced Mike Egli has been named to lead the combined Takeda and Nycomed commercial operation in Canada following the completion of Takeda’s acquisition of Nycomed, effective September 30, 2011.
Mike Egli most recently served as President of Nycomed in Canada. Previously, he was Managing Director of Nycomed Netherlands.
“Naming our Commercial country managers is a significant step in the integration of Takeda and Nycomed,” said Frank Morich, CEO, Nycomed and EVP, International Operations (Americas/Europe), Takeda Pharmaceuticals International, Inc. “This diverse and experienced team of leaders will help us realize the great potential of the new, combined Takeda/Nycomed organization and their commitment will prove invaluable as we focus on the core tenets of our Mid-Range Plan: innovation, culture and growth.”
The combined Takeda/Nycomed organization has significantly expanded its reach in Emerging Markets and deepened its position in Europe. It also strengthens global manufacturing capacities and brings together complementary therapeutic areas.
The combined company will employ more than 30,000 employees with an active presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management, as well as having a well-balanced presence in pharmaceutical markets of Japan, Asia, the United States, Europe and emerging markets.
About Takeda
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Takeda’s Forward-looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements regarding Takeda's plans, outlook, strategies, results for the future, and other statements that are not descriptions of historical facts. Forward-looking statements may be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," “assume,” "continue," "seek," "pro forma," "potential," "target," "forecast," “guidance,” “outlook” or "intend" or other similar words or expressions of the negative thereof. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.
The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.